Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, Lee FY, Gottardis MM, Clark E, Helman L, Attar RM, Dongre A, Carboni JM. Huang F, et al. Among authors: robinson d. Cancer Res. 2009 Jan 1;69(1):161-70. doi: 10.1158/0008-5472.CAN-08-0835. Cancer Res. 2009. PMID: 19117999 Free PMC article.
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C. Pistilli B, et al. Among authors: robinson d. Breast Cancer Res Treat. 2018 Apr;168(2):357-364. doi: 10.1007/s10549-017-4596-7. Epub 2017 Dec 2. Breast Cancer Res Treat. 2018. PMID: 29198055 Free PMC article. Clinical Trial.
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. André F, et al. Among authors: robinson d. J Clin Oncol. 2016 Jun 20;34(18):2115-24. doi: 10.1200/JCO.2015.63.9161. Epub 2016 Apr 18. J Clin Oncol. 2016. PMID: 27091708 Clinical Trial.
Survival in bilateral breast cancer.
Fracchia AA, Robinson D, Legaspi A, Greenall MJ, Kinne DW, Groshen S. Fracchia AA, et al. Among authors: robinson d. Cancer. 1985 Mar 15;55(6):1414-21. doi: 10.1002/1097-0142(19850315)55:6<1414::aid-cncr2820550641>3.0.co;2-d. Cancer. 1985. PMID: 3971312
The relationship between perceived discrimination and reported nutrient intake among pregnant individuals of minoritized racial and ethnic groups.
Johnson T, Kan AK, Bonner LB, Van Horn L, Kershaw KN, Grobman WA, Lindsay KL, Debbink MP, Mercer BM, Haas DM, Saade GR, Reddy U, Parry S, Simhan H, Robinson DT. Johnson T, et al. Among authors: robinson dt. J Acad Nutr Diet. 2024 Nov 12:S2212-2672(24)00984-5. doi: 10.1016/j.jand.2024.11.007. Online ahead of print. J Acad Nutr Diet. 2024. PMID: 39542239
The UBA1-STUB1 axis mediates cancer immune escape and resistance to checkpoint blockade.
Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu YM, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. Bao Y, et al. Among authors: robinson dr. Cancer Discov. 2024 Nov 14. doi: 10.1158/2159-8290.CD-24-0435. Online ahead of print. Cancer Discov. 2024. PMID: 39540840
5,515 results